Exome Asset Management LLC Makes New $5.27 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Exome Asset Management LLC purchased a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR) in the third quarter, Holdings Channel reports. The firm purchased 120,165 shares of the company’s stock, valued at approximately $5,274,000. Structure Therapeutics comprises about 3.5% of Exome Asset Management LLC’s holdings, making the stock its 4th largest position.

Several other large investors have also recently added to or reduced their stakes in GPCR. Geode Capital Management LLC lifted its position in shares of Structure Therapeutics by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after buying an additional 312 shares during the last quarter. Squarepoint Ops LLC boosted its stake in Structure Therapeutics by 4.5% during the 2nd quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock valued at $567,000 after purchasing an additional 617 shares during the period. Assetmark Inc. grew its position in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the last quarter. Sandia Investment Management LP acquired a new stake in Structure Therapeutics in the 2nd quarter valued at approximately $39,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Morgan Stanley assumed coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, HC Wainwright initiated coverage on Structure Therapeutics in a research note on Wednesday, December 4th. They set a “buy” rating and a $80.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $85.67.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $31.25 on Friday. The business has a 50-day moving average of $36.32 and a two-hundred day moving average of $39.18. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $62.74. The stock has a market capitalization of $1.79 billion, a P/E ratio of -42.23 and a beta of -3.41.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.